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Abstract 
Estrogens play a key role in cellular proliferation of estrogen-receptor-positive (ER+) breast cancers 
(BCs). Suppression of estrogen production by competitive inhibitors of the enzyme aromatase (AIs) 
is currently one of the most effective therapies against ER+ BC. Yet, the development of acquired 
resistance, after prolonged treatments with AIs, represents a clinical major concern. Serendipitous 
findings indicate that aromatase may be non-competitively inhibited by clinically employed drugs 
and/or industrial chemicals. Here, by performing in silico screening on two putative allosteric sites, 
molecular dynamics and free energy simulations, supported by enzymatic and cell-based assays, we 
identified five leads inhibiting the enzyme via a non-active site-directed mechanism. This study 
provides new compelling evidences for the existence of an allosteric regulation of aromatase and for 
the possibility of exploiting it to modulate estrogens biosynthesis. Such modulation can aptly 
reduce side effects caused by the complete estrogen deprivation therapy, and, possibly, delay/avoid 
the onset of resistance. 
 
Keywords: cytochromes P450; aromatase; molecular dynamics; aromatase inhibitors; docking; 
breast cancer; resistance onset; mixed inhibition mechanism. 
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1. Introduction 
The steroidogenic cytochromes P450 (CYP450s), CYP19A1 and CYP17A1, are relevant 
therapeutic targets for hormone-related tumors, such as breast and prostate cancers. In particular, 
CYP19A1, commonly referred as human aromatase (HA) enzyme, promotes the conversion of 
androgens (androstenedione (ASD), testosterone and 16α-hydroxytestosterone), into estrogens, 
(estrone, 17β-estradiol and 17β,16α-estriol, respectively) via a three-step catalysis, requiring 
molecular oxygen, protons and electrons.1,2 While the protons necessary for catalysis are supplied 
via a substrate/water channel opening in the vicinity of the active site,3,4 electrons are provided by a 
NADPH cytochrome P450 reductase (CPR) for all microsomal CYP450s. Once synthesized, 
estrogens bind to estrogen receptor (ER), whose major form in breast cancer (BC) is ERα, encoded 
by the gene ESR1. ERα is a transcription factor, controlling genes associated with cell survival and 
proliferation.5 This receptor stimulates cellular growth and proliferation, thus playing a critical role 
in estrogen receptor positive (ER+) BC, where abnormal concentrations of estrogens are produced 
by HA. 
BC is the most frequent female cancer, accounting for nearly 30% of all cases in women,6 among 
which about 60% and 75% of BCs in pre- and post-menopausal women, respectively, are ER+. 
Three types of endocrine therapies currently employed to treat ER+ BC patients are based on the 
use of: (i) selective estrogen receptor modulators (SERMs), such as tamoxifen, which block 
estrogen-induced ERα activation;7 (ii) selective estrogen receptor degraders (SERDs), such as 
fulvestrant, which antagonize and degrade ERα,8 and (iii) HA inhibitors (Aromatase Inhibitors, 
AIs), which counteract estrogen biosynthesis.9 The clinical use of AIs such as letrozole (LTZ), 
anastrozole (ANZ) and exemestane (EXE, Figure 1) represented a major breakthrough in the 
treatment of ER+ BC as these drugs display satisfactory clinical efficacy and manageable toxicity 
profiles.10-12 Nevertheless, complete estrogen deprivation induced by their administration leads to 
troublesome side effects (i.e. exacerbation of menopausal symptoms, osteoporosis, loss of bone 
density and musculoskeletal complaints). Alarmingly, despite initial therapeutic benefits, acquired 
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resistance leading to disease relapse may arise in metastatic BC patients after prolonged AIs 
treatment. The molecular details of the complex scenario underlying resistance onset remains 
elusive,13 even though large-scale genomic studies identified some aggressive ERα polymorphisms 
making the receptor intrinsically active even in the absence of estrogens.14 As such, the 
development of novel therapeutic approaches able to modulate excessive estrogen biosynthesis with 
alternative molecular mechanisms represents both a current major clinical challenge to treat ER+ 
BC and a novel therapeutic opportunity. 
 
 
Figure 1. Molecular structures of the endogenous substrate (ASD) of the enzyme aromatase (HA) along with 
the most clinically relevant aromatase inhibitors (AIs; LTZ, ANZ and EXE) and selective estrogen receptor 
modulators (SERMs; TAM and END). 
 
Since the appearance of its first crystal structure,15 HA has been object of intense investigations 
tackling several functional aspects,16-19 and searching for novel competitive AIs.20-24 Additionally, it 
was recently proposed that endoxifen (END), a tamoxifen metabolite belonging to SERMs, and 
letrozole (LTZ, Figure 1), the most prominent HA inhibitor, may exert a non-competitive/mixed 
inhibition mechanism.25,26 The existence of this type of inhibition was further corroborated by 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 4
kinetic studies on agricultural fungicides (bifonazole, imazalil, and flusilazole), and on industrial 
chemicals (triclocarban, an antimicrobial additive present in many industrial products).26,27 
Exploiting non-competitive HA inhibition offers attractive advantages over its competitive 
counterpart as the former can reach a maximal inhibitory potency without completely abrogating 
estrogen production. This can expectedly result in the reduction of the side effects caused by 
conventional AIs and, possibly, in delaying/avoiding the onset of resistance. In this context, the 
rational search and design of mixed/non-competitive drug-candidates implies the non-trivial 
identification of allosteric sites.28 In a previous study we have identified, using computational 
methods, three potential allosteric pockets,29 two of them being involved in pivotal aspects of HA 
catalysis: (a) Site 1, lying along one of the possible substrate access channel to the catalytic site;30 
and (b) Site 2, also referred as the heme-proximal cavity and corresponding to the CPR binding site, 
which is believed to participate in the electron transfer from CPR to HA heme (Figure 2, HA 
residues composing Site 1 and 2 are reported in Table S1). Importantly, the existence of the latter 
site was confirmed by a recent crystal structure, trapping polyethylene glycol inside this cavity.31  
 
Figure 2. Model of HA enzyme embedded in a POPC (phosphorous and oxygen atoms are shown as tan and 
red spheres)/CHL (yellow surface) membrane. Site 1 and 2 are shown as orange and magenta transparent 
surfaces, respectively, while heme and ASD are displayed in a van der Waals (vdw) representation. 
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With the aim of setting the stage for the discovery of new small-molecule therapeutic tools to tackle 
BC, here, we developed an integrated computational and experimental protocol based on: (i) 
structure-based virtual screening (VS) on libraries of commercial compounds; (ii) ensemble 
docking on distinct HA structures, targeting the two putative allosteric sites; (iii) cumulative 10 µs-
long force field (FF) based atomic-scale molecular dynamics (MD) simulations aimed at refining 
docking poses of selected compounds; (iv) spectrofluorometric and cell-based assays to establish 
the activity of the best-ranked molecules obtained from our in silico studies; (v) measurements of 
the inhibition kinetics; (vi) refinement of the binding pose, and estimation of the dissociation free 
energy barrier for the best drug-candidate via metadynamics (MTD) simulations.  
As a result, five molecules inhibited HA in the low µM range via a non-active site-directed 
mechanism, strikingly providing the first compelling instance for the feasibility and exploitation of 
this alternative regulation mechanism of estrogen biosynthesis. Hence, our outcomes can lay the 
foundation for developing unexplored therapeutic strategies to treat ER+ BC, possibly able of 
delaying/avoiding the onset of resistance, which frequently develop under the pressure of current 
therapies. 
 
2. Results 
2.1. Binding to the two putative allosteric pockets: the access channel cavity (Site 1) 
A 400 ns MD simulation was initially performed on a HA model (PDB ID 3EQM)15 embedded in a 
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine/cholesterol (POPC/CHL) membrane (Figure 2, 
RMSD plot is reported in Figure S1), with ASD bound to the active site. The distance between the 
center of mass of HA and the membrane and the tilt of the heme plane with respect to the 
membrane were consistent to previous studies (Table S2), confirming the reliability of our 
model.19,32,33  
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On the basis of recent evidence envisioning a mixed/non-competitive inhibition mechanism of 
LTZ,26 we initially docked the latter into Site 1, using an induced fit protocol,34 to assess whether 
this was a viable binding pocket. The best-ranked LTZ pose was then relaxed by 400 ns-long MD 
simulation (see RMSD in Figure S1). Strikingly, after about 100 ns, LTZ increasingly penetrates 
into Site 1, displacing all the water molecules present within the cavity. In the absence of LTZ, Site 
1, indeed, displays a network of water molecules lying between Asp309 and Arg192, (Figure 3a, b) 
as evidenced by radial distribution function (g(r)), (Figure 3d) calculated along the MD 
trajectories,15 and also observed in the enzyme crystal structure (pdb ID 3EQM). These water 
molecules are critical for HA function, as they supply the protons necessary for its catalysis,4,35,36 
and lay between Asp309 and Arg192, which mutagenesis studies identified as essential residues for 
enzymatic activity.37 Upon LTZ binding to Site 1, the g(r) peaks are shifted to a larger distance 
(Figure 3d), clearly underlining that the drug displaces the waters molecules from Site 1. This 
hampers the delivery of protons to the substrate, one of the key requirements for estrogen 
production. 
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Figure 3. Representative structures of Site 1: the water network connecting Asp309 and Arg192 in the free 
enzyme (a) is displaced upon binding of LTZ (b) and END (c) to Site 1. Heme atoms, ASD, LTZ and END 
along with residues lining Site 1 are shown in licorice and colored by atom name, protein ribbons are shown 
in violet. d) Radial distribution function, g(r), of the water molecules from the carboxyl oxygens of Asp309. 
Black, red and green lines refer to the apo, LTZ- and END-bound enzyme, respectively. 
 
In order to inspect if the absence of the endogenous substrate, ASD, in the active site could affect 
LTZ binding pose, we also performed additional 200 ns of MD after ASD removal. As a result, 
LTZ stably sits within Site 1 retaining its binding pose (RMSD 0.88 Å), while the active site 
maintains its shape (Figure S2).  
To further validate our findings, we also considered the binding of both E and Z endoxifen isomers 
to Site 1. In line with our previous study,29 Z-END dissociates within 50 ns of MD simulation, 
while E-END (defined simply as END hereafter) firmly binds to this allosteric site for 400 ns-long 
MD simulation (Figure 3c) and, even more pronouncedly than LTZ, displaces the water molecules 
from the access channel (Figure 3d). Hence, upon binding to Site 1, END and LTZ may 
prevent/reduce catalysis via a similar mechanism, which consists in hampering the proton delivery 
necessary for estrogen biosynthesis.  
Finally, since Site 1 lies along one of the substrate access/egress channel30 and a two-steps substrate 
binding kinetic has been demonstrated for HA,38 we additionally docked ASD to Site 1 and verified 
its stability by performing 200 ns-long MD simulation. Our simulation confirm that ASD may bind 
to Site 1 along its entrance/egress route (Figure S3). 
 
2.2. The heme-proximal cavity (Site 2) 
Following the same protocol adopted above, LTZ was docked to Site 2, where it remained stably 
bound for 400 ns of MD. In the best-ranked pose, LTZ lies between Lys440 and Tyr361 (Figure 
4a). These are again two critical residues for estrogen biosynthesis, as evidenced by mutagenesis 
studies,37 believed to stabilize the interactions between HA and its redox partner CPR. Hence, the 
binding of a drug at this site may hamper the formation of the CPR/HA adduct and/or affect the 
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electrons flow necessary for catalysis. Similarly to LTZ, also END stably binds in between Lys440 
and Tyr361 (see Figure 4b).  
 
 
Figure 4. Representative snapshots extracted from the MD simulation of the binding of LTZ (a) and END 
(b) to Site 2. Heme atoms, ASD, LTZ and END along with residues lining Site 2 are shown in licorice and 
colored by atom name, protein ribbons are shown in violet 
 
The binding free energy (∆Gb), as calculated with Molecular Mechanics Generalized Born Surface 
Area (MM-GBSA),39-41 of LTZ in the two allosteric sites reveals its higher affinity for Site 1 (Table 
1), while END does not exhibit a clear preference for any of the two sites (Table 1). 
 
2.3. Non-active site-directed inhibitors: identification and experimental validation 
Virtual screening (VS) simulations were performed to identify drug-like molecules binding to both 
allosteric pockets, using three distinct target conformations (ensemble docking, see methods) in 
order to account for receptor flexibility. Among the best 100 compounds we selected, upon visual 
inspection, 42 molecules according to their ability to interact with critical residues involved in HA 
catalysis (i.e. Asp309, Arg192, Tyr361 and Lys440), and to maximize their structural diversity. The 
binding mode and the relative energy ranking of these molecules were then refined by performing 
100 ns-long MD simulations of each drug/HA adduct. Twenty-one molecules spontaneously 
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dissociated from HA within this simulation time, underlying the importance of accounting for 
protein dynamics whilst searching for non-active site-directed inhibitors.42,43 
The other molecules, which remained stably bound to HA in this simulation time, were re-ranked 
by their relative ∆Gb, computed with MM-GBSA (Table S3). Among them, the 18 best-ranked 
molecules were, then, tested as potential HA inhibitors, at initial concentrations of 100 and 200 µM 
with an HA fluorimetric kit, using LTZ and END as controls. Six molecules (ZINC database: 
Z95360272, Z82120489, Z97377720, Drugbank: Taxifolin, NCI database: 317017, 681288) 
showed activity at both concentrations (Table S3). Taxifolin was excluded from further tests due to 
the similarity with the endogenous substrate ASD, which would most probably lead to a 
competitive mechanism of inhibition. Next, the remaining molecules were tested at different 
concentrations (ranging from 1 to 200 µM) to determine the IC50 value (i.e. the concentration able 
to inhibit HA catalytic activity by 50%) of each compound. All molecules showed IC50 values in the 
µM range (Table 1 and Figure S4). Consistent with its high inhibitory potency, LTZ was active in 
the nM range,26 while, in contrast to previous studies, END showed activity only at a concentration 
of 200 µM.25 
 
Table 1: Compounds displaying inhibitory activity in fluorimetric assays. Database codes of the active drug-
like molecules, binding free energies (∆Gb, kcal/mol) computed with the MM-GBSA method, IC50 
fluorimetrically derived, GI50 calculated on ER+ (MCF-7) and ER- (MDA-MB-231) cell lines, and the Site 
in which the molecules were screened are reported from left to right columns, respectively. 
Compound Database 
Code 
∆Gb 
(kcal/mol) 
IC50 (µM) 
on HA 
GI50 (µM) 
on MCF-7 
GI50 (µM) 
on MDA-
MB-231 
Site 
LTZ - -21.7 ± 2.5   0.0126 4.1 ± 1.1 ˃10 1 
-17.1 ± 2.3 2 
END - -37.1 ± 3.6  6.125 - - 1 
-37.1 ± 2.9 2 
1 ZINC-95360272 -29.8 ± 3.2 5.1 ± 0.6 21.3 ± 0.009 58.0 ± 0.240 1 
2 NCI-317017 -36.2 ± 4.1 11.0 ± 4.0 17.9 ± 0.5 6.8 ± 0.004 1 
3 ZINC-82120489 -24.2 ± 3.9 20.9 ± 1.6 ˃200 ˃200 1 
4 NCI-681288 -30.7 ± 4.3 95.3 ± 6.6 22.1 ± 0.54 16.2 ± 0.009 2 
5 ZINC-97377720 -26.6 ± 2.8 21.7 ± 3.9 66.4 ± 0.035 >200 2 
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Among these compounds, three (1, 2 and 3) molecules were identified by performing VS on Site 1, 
while the remaining two (4 and 5) on Site 2. Thus, the molecules targeting Site 1 establish 
interactions with Arg192, Asp309, Glu483 (H-bonds) and His480 (π-π stacking), while those 
binding Site 2 establish interactions with Tyr361, Gln428 (H-bonds) and Phe430 and Tyr361 (π-π 
stacking) (Figure 5). A summary of all residues involved in the intermolecular interactions for each 
allosteric Site is reported in Table S4. 
All active molecules and LTZ were also tested for their ability to inhibit the growth of prototypical 
ER+ (MCF-7) and ER- (MDA-MB-231) BC cell lines (Table 1 and Figure S5). Compounds 1, 2, 4 
and 5, although to a different degree, were active in reducing the growth of MCF-7 cells, as 
indicated by the different Grow Inhibition activity (GI50) values (i.e. the test agent concentration 
able to inhibit growth by 50%). Moreover, consistently with the lack of ER expression, MDA-MB-
231 cells were less sensitive than MCF-7 cells to 1 and completely resistant to 5 (Table 1 and 
Figure S5), which represent the best compounds for each site. These important results suggest the 
correct engagement of the desired target by the selected compounds. 
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Figure 5. Ligand interaction diagrams of the active drug-like molecules identified. H-bonds are represented 
as purple arrows, while stacking interactions are depicted in green. Site of binding and commercial code of 
the molecules is also reported on the bottom. 
 
Enzymatic kinetics analyses were performed on these five active compounds to assess their type of 
inhibition mechanism. These molecules were tested at constant concentration (set at 33% of their 
IC50 value) and at different concentrations of substrate, which ranged from 0.15 to 3.6 µM (Figure 
S6). The kinetic parameters were obtained both as the median values from a Cornish-Bowden direct 
linear analysis of the experimental data44 and from Michaelis-Menten analysis (Table 2).  
 
Table 2: Kinetic parameters of the inhibited reactions. *:Median values from the ordered series of the 
intersection coordinates of all the possible couples of straight lines of equation:  =  +	



, 
obtained from each couple of experimental points {vi;Si}, according to the Cornish-Bowden direct linear 
method. §: values from the regression of experimental data to the Michaelis-Menten equation. 
 
*
 
(Fl.units msec-1) 

§
 
(Fl.units msec-1) 

*
 
(µM) 

§
 
(µM) 
No inhibitor 91.5 93.3 ± 1.3 1.92 2.73 ± 0.09 
1 15.1 19.3 ± 0.4 1.28 2.51 ± 0.13 
2 16.2 21.5 ± 0.3 1.13 2.31 ± 0.14 
3 50.7 64.6 ± 1.5 1.30 2.78 ± 0.17 
4 60.6 79.3 ± 0.3 2.16 3.93 ± 0.06 
5 78.7 85.2 ± 0.3 3.46 3.54 ± 0.03 
 
This analysis revealed that the maximum rate of the non-inhibited enzyme reaction is clearly no 
longer attainable in the presence of the inhibitors. This is particularly evident with 1 and 2, where 
the maximum rate is about 16% of the non-inhibited one. The apparent values of Km are only 
slightly affected by inhibition with 1, 2 and 3, while a somewhat larger effect is observed with 4 and 
5, which are predicted to interact at Site 2. In this case the affinity for the substrate seems to 
decrease by less than two times. This finding may be in line with an allosteric communication 
between the proximal cavity and the active site recently identified in other CYP450s.45 
Although preliminary, these measurements clearly support the occurrence of a mixed mechanism of 
inhibition for all tested molecules. At the same time, these results are not consistent with a 
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competitive inhibition, supporting our initial working hypothesis for the discovery of non-
competitive/mixed HA modulators. 
 
2.4. Refinement of the binding poses and dissociation kinetics 
Target and ligand flexibility is an essential feature to identify allosteric pockets and drug-like 
molecules targeting them. In this context, the ligand dissociation kinetics is increasingly being 
recognized as one of the key traits in drug efficacy optimization studies.46-48 Hence, we have 
employed MTD simulations, which by enhancing the exploration of the binding pocket and of the 
ligand dissociation route, can provide a refinement of the inhibitor binding pose, and furnish 
information about its dissociation free energy barriers (∆Gd#). These simulations were needed since 
LTZ and the identified inhibitors displayed calculated ∆Gb values with opposite trend with respect 
to their measured IC50s and in order to possibly infer drug efficacy by evaluating the relative 
unbinding kinetics of the newly discovered inhibitors with respect to LTZ, which has a proved 
clinical efficacy. To this end, MTD simulations were performed for the best lead identified (1) and 
for LTZ bound to Site 1. These disclosed that 1 assumes a slightly refined binding pose with respect 
to those obtained from combined docking and MD simulations (Figure S7). Moreover, the two 
compounds dissociate from Site 1 with a similar free energy cost (∆Gd# of 11.4 ± 1.4 and 11.8 ± 1.3 
kcal/mol, respectively). Hence, these results support the potential of our best lead molecule which, 
besides displaying a good binding affinity towards the target (∆Gb), is characterized by a 
dissociation kinetic from its target site similar to that of a drug in clinical use.30 
 
3. Discussion 
Despite the extended survival rate achieved for patients in the last decades, BC remains a 
frightening disease, being the most common female cancer and the second cause of cancer death in 
women worldwide. Approximately 70% of BC patients are affected by ER+ carcinomas for which 
one of most exploited therapeutic approach relies on abrogating estrogen biosynthesis via HA 
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inhibition. Although AIs-based therapies show higher clinical efficacy and induce less severe side 
effects than SERMs, the development of acquired resistance, after prolonged treatments, remains 
the main concern for ER+ BC therapy. Acquired resistance to AIs (as well as to SERMs) is due to 
an intricate and incompletely understood interplay of different mechanisms, which impact on 
multiple competing biological pathways.13 One major route is represented by the occurrence of 
aggressive ERα somatic mutations, which are often developed in metastatic BC patients (up to 
40%) under the evolutionary pressure of prolonged therapies relying on estrogen deprivation. These 
mutations make ER intrinsically active. As a result, BC becomes insensitive to estrogens 
suppression. 
With the aim of exploring alternative en-route to novel therapeutic approaches against BC, here we 
provide a proof-of-principle study, which lays the foundation for novel regulatory strategies of 
estrogen biosynthesis potentially able to avoid the onset of resistance issues. This relies on a non-
competitive/mixed inhibition of HA catalysis. Exploiting allostery to modulate estrogen 
biosynthesis offers major advantages with respect to conventional competitive drugs in that: (i) 
allosteric drugs can reach the maximal inhibitory power without complete inhibition of estrogen 
production, (as instead competitive inhibitors do) (ii) they may not be outcompeted at higher 
concentrations of natural substrates and, (iii) targeting allosteric sites, which are less conserved 
across protein families compared to classical active sites, may offer the possibility of developing 
selective drugs, limiting off-target interactions and side effects. As such, we suggest that our 
approach represents a viable and valuable strategy for developing alternatives to current therapeutic 
options. 
By introducing a computational protocol that integrates ensemble docking, to account for receptor 
flexibility, cumulative 10 µs MD simulations to consider allosteric site plasticity and adaptability to 
the screened drug-like compounds, binding and dissociation free energy calculations, we have 
identified new leads active in the µM range, fitting in two allosteric pockets. The best compounds 
identified from our combined in silico and experimental assays (1-3) target Site 1, displaying IC50 
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values in the low µM range,1 in line with the challenging and flexible nature of allosteric pockets, 
which usually are targeted by the ligands with lower affinity.45 Importantly, enzymatic kinetics 
assays suggest that a mixed inhibition mechanism may be operative for all the identified active 
molecules. Furthermore, our simulations rationalize their possible mechanism of action, pinpointing 
that, upon binding to Site 1 and 2, these compounds may hamper catalysis by interfering with the 
delivery of the protons, and electrons, respectively, necessary for estrogen production. Among 
those, molecules targeting Site 1 (1-3) have lower IC50, GI50 and larger ∆Gb, pointing to this site as 
the most promising target candidate for future drug optimization studies. Remarkably, cell grow 
inhibition assays disclose that our best leads, 1 and 5, targeting Site 1 and 2, respectively, are more 
effective in reducing the growth of MCF-7 ER+ cells with respect to MDA-MB-231 ER- ones.49 
Our protocol underscores the necessity of accounting for protein dynamics via atomic-scale MD 
simulations in order to refine docking poses and eliminate false positives (i.e. highly ranked 
compounds by rigid docking algorithms/conventional scoring functions, which quickly dissociates 
from their target when solvent, receptor flexibility and finite temperature effects are accounted). 
Interestingly, the ligand dissociation rate is often used as an indicator of the residence time of a drug 
on its receptor, thus becoming a new paradigm in drug optimization studies aiming at increasing the 
desired biological effect.50 By exploiting a MTD-based protocol, which provides an evaluation of 
ligand dissociation rate, by computing its dissociation free energy barrier (∆Gd#), we disclose that 1 
and LTZ, that has a well-established clinical efficacy, have similar residence time at Site1.  
The relevance of allostery has at times been considered in CYP450s, which besides participating to 
steroidogenesis, such as HA or CYP17A1, are also involved in the metabolism of exogenous 
compounds. While distinct allosteric sites types have been identified in this latter CYP450s 
category,51-53 the impact on enzymatic activity induced upon effectors binding to those sites remains 
controversial.54 An allosteric modulation of CYP450s catalysis has been, instead, suggested upon 
                                                 
1
 We remark that compound 1, which is optically active, was tested as a racemic mixture, but according to our 
calculation only one enantiomer (1S) can tightly bind in Site 1, suggesting that its inhibitory power will be even higher 
that that measured by IC50 and GI50. Compound 3 was purchased as a single diastereoisomer (3R, 4R). 
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the binding of protein redox partner (CYPb5) to CYP17A1,55 in addition to the serendipitous 
observation of non-competitive inhibition kinetics for HA exerted by drugs and industrial 
chemicals.27 Despite these evidences support the hypothesis of exploiting allostery for CYP450s 
functional regulation, to the best of our knowledge no effective non-competitive/mixed inhibitor of 
any CYP450 has been hitherto identified in rational drug discovery studies. 
Hence, our results, besides corroborating the existence of two functioning allosteric sites in HA, 
identify for the first-time drug-like mixed inhibitors of this enzyme with a fully rational approach, 
setting the stage for the development of novel regulatory strategies of estrogen biosynthesis to fight 
ER+ BC. This may, eventually, offer precious therapeutic alternatives depending on disease 
progression and on patients’ genetic signatures, which may encode for the ERα isoforms refractory 
to conventional therapies. 
 
4. Materials and Methods 
4.1. In silico screening 
The NCI (https://cactus.nci.nih.gov/download/nci/), drugbank56 and the clean lead subset of the 
ZINC databases57 were used as ligand libraries for VS studies. In order to take into account 
ionization and tautomerization states of the compounds, Schrodinger Suite 2017-1 Epik tool was 
used,58 with a maximum number of 4 structures for each molecule. Compounds were filtered using 
the Schrodinger Ligfilter tool.58 Ligands that violated Lipinski’s rule of five, in order to eliminate 
compounds possessing poor absorption and permeation,59 as well as compounds with more than 10 
rotatable bonds, were discarded, since high ligand flexibility implies higher entropic contributions 
and reduce oral availability.60 As well, Qikprop58 was employed to predict LogP values of the 
compounds.  
In silico screening of the above-mentioned libraries was performed on Site 1 and Site 2. A list of the 
residues composing these two sites and used for grid generation is reported in Table S1.29 
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Accounting for receptor flexibility during in silico screening of ligands targeting allosteric pockets 
is highly recommended.28,61,62 Hence, we performed ensemble docking simulations by selecting 
three structures of the target: (i) the HA crystal structure (pdb ID 3EQM),15 (ii) the most 
representative protein structure as obtained from a cluster analysis of its MD simulation in the 
presence of a membrane mimic and (iii) the most representative structure obtained from the MD 
simulations of HA in the presence of LTZ bound either to Site 1 or to Site 2. The latter structures 
allow to account also for the induced fit effects imposed by LTZ, which is an already established 
mixed/non-competitive inhibitor.26 All water molecules were deleted before starting docking 
calculations. A van der Waals (vdW) radius scaling factor of 0.80 Å for protein and ligands atoms 
having a partial charge less than 0.15 was used in order to account for protein flexibility. A VS 
workflow58 based on three subsequent steps of docking with increasing level of accuracy, was 
adopted using the Glide program.63 Namely, (i) a fast high-throughput virtual screening (HTVS) 
was initially performed in order to efficiently select promising ligands among millions of 
compounds-large libraries; (ii) 5 % of the best ranked ligands are retained and a single precision 
(SP) docking calculation is performed; (iii) the top 5 % of the resulting compounds are screened 
using the extra precision (XP) protocol. This latter should eliminate false positives by using a more 
extensive sampling and more accurate scoring functions. The resulting molecules were sorted 
according to GlideScore scoring function, and, after visual inspection, the poses of the top-ranked 
42 compounds were refined by performing classical MD simulations as detailed below.  
An induced fit protocol34 was used to dock LTZ and END, in Site 1 and Site 2, since they are 
suggested to be non-competitive/mixed inhibitors,25,26 and the substrate, ASD, in Site 1. An initial 
SP docking was performed with a softened vdW radius scaling of 0.50 for ligands and protein 
atoms having a partial atomic charge of 0.15. Afterwards, 100 poses were submitted to Prime64 for 
prediction of new side chains orientation for the residues within a shell of 6 Å from the ligand 
center of mass. Finally, a Glide re-docking was performed for HA/ligand adducts with score laying 
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within 30 kcal/mol from the best one. The best ranked poses of the ligands inside Site 1 and Site 2 
were subjected to MD simulations.  
 
4.2. Classical MD simulations 
An equilibrated HA model was taken from our previous work29 (PDB ID 3EQM)15 and, by using 
the CHARMMGUI webserver,65 it was embedded in a POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine) membrane containing 6 wt% of cholesterol (CHL) in order to mimic the 
endoplasmic reticulum membrane.66 Physiological protonation states were calculated with the 
webserver H++.67 Asp309 was considered in its neutral form consistently with literature studies.3,68 
Parm99SB AMBER FF was employed for the protein,69,70 lipid14 for the lipids,71 Shahrokh et al. 
parameters for the heme moiety and Cys437.72 Most simulations were done in presence of the 
substrate ASD for which the general Amber FF (GAFF) was used.73 ESP charges74 were calculated 
by performing geometry optimization of the substrates at Hartree-Fock level of theory using a 6-
31G* basis set with the Gaussian 09 software75 and were later transformed in RESP charges with 
the Antechamber module of ambertools 16.76 The system was solvated by water molecules (TIP3P 
model),77 leading to a total of 131454 atoms. Topology, built with the ambertools 16, was later 
converted in a GROMACS format using the software acpype.78 MD simulations were performed 
with GROMACS 5.0.4.79 An integration time step of 2 fs was used and all covalent bonds involving 
hydrogen atoms constrained with the LINCS algorithm. Particle Mesh Ewald algorithm80 was used 
in order to account electrostatic interactions. Simulations were performed in the isothermal-isobaric 
NPT ensemble, at a temperature of 300 K, under control of a velocity-rescaling thermostat.81 
Preliminary energy minimization was done with the steepest descend algorithm. An initial 
equilibration of the membrane was performed for 100 ns with the protein atoms harmonically 
restrained with a force constant of 1000 kJ mol−1 nm−2, reaching a constant value (92 × 92 × 151 
Å3) of the simulation box size. Constraints were then released, and the system was slowly 
thermalized to the target temperature of 300 K within 10 ns. Then, it was relaxed by performing a 
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400 ns MD simulation. In order to assess the stability of the docking poses obtained from the VS of 
the NCI, drugbank and ZINC databases the 42 best-ranked ligands were inserted into this 
equilibrated membrane and each one underwent 100 ns classical MD simulations.  
 
4.3. Metadynamics (MTD) simulations 
In order to further refine the binding poses of LTZ and the compound with the best inhibitory 
activity (1) we have performed FF based MTDs simulations. In particular, MTDs runs of 50-100 ns 
were performed to refine the binding pose and study ligand dissociation with GROMACS 5.0.4 
using the PLUMED 2.0 plugin.82 Two collective variables (CVs) were used: the first (CV1) 
describes the number of hydrophobic contacts between the ligands and Site 1, computed as a 
coordination number; the second (CV2) corresponds to the distance between the center of masses 
(COM) of the protein and the ligand. Gaussian hills having a height of 0.6 kj/mol and widths of 
0.016 and 0.095 (LTZ), 0.024 and 0.160 (1), were added respectively for CV1 and CV2 every 4 ps 
of MD. A harmonic wall was used to restrain the exploration of the FES on CV2. Three replicas of 
the MTD simulations were performed, starting from different frames as extracted from the 
equilibrated trajectory and the uncertainty of the dissociation free energy barriers (∆Gd#) were 
estimated from the standard deviation of the barriers obtained out of the three replicas, following 
previous simulations studies.4,83,84 
 
4.4. Analysis 
Cluster analysis, root mean square deviation (RMSD), radial distribution function (g(r)) of the MD 
trajectories were done with the g_cluster tool, based on the Daura et. al algorithm,85 g_rmsd, and 
g_rdf as implemented in the GROMACS 5.0.4 program. Molecular Mechanics Generalized Born 
Surface Area (MM-GBSA) free energy calculation were performed with the MM_PBSA.py tool of 
Amber 12 program, following a procedure successfully applied in previous studies,29,86 keeping 
parameters at the default values.87 The distance of the protein from the membrane, is obtained as the 
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distance between the center of mass of HA and the center of mass of the membrane. The heme tilt 
angle, is represented by the angle between the heme plane, defined by heme nitrogen atoms, and the 
z-axis. Visualization of the MD trajectories and images were done with the VMD program.88 
 
4.5. HA inhibition and kinetics assays 
Inhibition of HA was quantified by the Aromatase Inhibitor Screening Kit (BioVision Inc., San 
Francisco, USA), using a fluorogenic substrate that is converted by HA into a highly fluorescent 
metabolite. Briefly, after the reconstitution of the reagents, a standard curve was generated by 
diluting the fluorescent standard. Test compounds were dissolved in DMSO at a final concentration 
of ≤ 0.25% (v/v), after having verified that such concentration of solvent does not affect the enzyme 
activity in significant way. Each mother solution was diluted in aromatase assay buffer to obtain a 
range of concentrations for generating a multi-point dose-response curve. The reaction was 
prepared by adding Aromatase mix (containing Recombinant Human Aromatase (2X), Aromatase 
assay buffer and NADPH-generating system) to test compounds, inhibitor control, background 
control and positive control (1 µM LTZ). The reaction mixture was preincubated at 37°C for 10 min 
to allow test compounds to interact with HA, then, reaction initiated after the addition of 30 µl of 
Aromatase Substrate/NADP+ mixture (containing buffer, aromatase substrate and β-NADP+ 100X 
stock). Assays were conducted in 96-well microtiter plates (Corning Incorporated, Corning, ME, 
USA) in a final reaction volume of 100 µl/well. Sample fluorescence was measured using a 
TECAN Ultra microplate reader (Tecan Trading AG, Switzerland) at dual wavelengths of 488/527 
nm for 60 min. Results were expressed as relative fluorescence units (RFUs). Experiments were 
performed in triplicate and the average values were used to construct the dose-response curves. The 
percentage of inhibition was calculated as the ratio between the RFUs of control and test compound, 
according to the manufacturer’s instructions. 
The 20 molecules selected on the basis of our VS protocol were purchased from Enamine, 
Chembridge, and Sigma-Aldrich or donated by the NCI (Table S5). Tests were initially performed 
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at 200 and 100 µM concentrations of the inhibitor to identify potentially active molecules. All chiral 
compounds were tested as racemic mixtures. The five compounds that showed ≥ 40% inhibition at 
the concentration of 100 µM were then tested at different concentrations (200, 100, 50, 10, 1 and 
0.1 µM). For each compound, the concentration able to inhibit HA activity by 50% (IC50) was 
calculated by nonlinear regression of the experimental data to a tetraparametric logistic curve 
(SigmaPlot 13.0 - Systat Software Inc.). 
To obtain a preliminary analysis of HA inhibition mechanism, we performed several kinetic runs at 
constant test compound (set at 33% of their IC50 values) and at different substrate concentrations 
ranging from 0.25 to 6 times the approximate value of Km declared by the supplier of the screening 
kit. The substrate and inhibitors concentrations were chosen within the limitations imposed by 
compound solubility; 1% acetonitrile was used in all the measures. Under such conditions, the % 
inhibition decreases as the substrate concentration increases in the case of competitive inhibition, 
while it remains constant if the inhibition is noncompetitive and increases if the inhibition is 
uncompetitive.44,89 It is important to remark that, among these five molecules, compounds 2 and 4, 
possessing a quinone moiety, are reported as potential PAINS (Pan Assay Interference 
Compounds), and consequentially could interfere with biochemical high throughput screenings.90 
 
4.6. Cell growth inhibition assay 
The human breast cancer cell lines MCF-7 (ER+) and MDA-MB-231 (ER-) were obtained from the 
American Type Culture Collection (Rockville, MD, USA). Tumor cells were seeded in triplicate in 
12-well plates (50000 cells/well) and 24 h later exposed for 72 h to increasing concentrations (from 
0.01 to 10 µM, 1 to 200 µM and 10 to 200 µM for LTZ, compounds 1 - 4 and 5, respectively). 
Tumor cells were harvested using trypsin and counted with a cell counter (Beckman Coulter, 
S.p.A., Milan, Italy). Three independent experiments (each in triplicate) were carried out and the 
average values were used to construct dose-response curves and calculate the concentration of 
compound able to inhibit cell growth by 50% (GI50).  
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• In silico screening of allosteric pockets of the aromatase enzyme. 
 
• Five molecules inhibit the enzyme via a non-active site-directed mechanism. 
 
• A preferential inhibition of ER+ (MCF-7) cell lines was observed. 
 
• Kinetic assays confirmed a non-competitive/mixed mechanism of inhibition. 
 
• This mechanism may reduce side effects caused by estrogen deprivation therapy. 
 
